Advertisement
New Zealand markets closed
  • NZX 50

    11,864.89
    -7.75 (-0.07%)
     
  • NZD/USD

    0.6144
    -0.0027 (-0.43%)
     
  • NZD/EUR

    0.5733
    -0.0008 (-0.14%)
     
  • ALL ORDS

    7,974.80
    -27.70 (-0.35%)
     
  • ASX 200

    7,724.30
    -25.40 (-0.33%)
     
  • OIL

    78.49
    -0.13 (-0.17%)
     
  • GOLD

    2,348.40
    +30.40 (+1.31%)
     
  • NASDAQ

    19,659.80
    +82.88 (+0.42%)
     
  • FTSE

    8,146.86
    -16.81 (-0.21%)
     
  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     
  • DAX

    18,002.02
    -263.66 (-1.44%)
     
  • Hang Seng

    17,941.78
    -170.85 (-0.94%)
     
  • NIKKEI 225

    38,814.56
    +94.09 (+0.24%)
     
  • NZD/JPY

    96.6520
    -0.1680 (-0.17%)
     

3 Things About Eli Lilly That Smart Investors Know

3 Things About Eli Lilly That Smart Investors Know

Eli Lilly (NYSE: LLY) is getting a lot of Wall Street attention again. Eli Lilly's drug development pipeline is as big as they come, and that means plenty of new medicines are likely to hit the market in any given period. Within the next year, Lilly could commercialize tirzepatide for obesity, donanemab for Alzheimer's disease, empagliflozin for chronic kidney disease, and lebrikizumab for atopic dermatitis.